Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg
Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent
For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
